Unknown

Dataset Information

Renoprotective effects of a novel cMet agonistic antibody on kidney fibrosis.


ABSTRACT: Hepatocyte growth factor (HGF) and its receptor, cMet, activate biological pathways necessary for repair and regeneration following kidney injury. Because HGF is a highly unstable molecule in its biologically active form, we asked whether a monoclonal antibody (Ab) that displays full agonist activity at the receptor could protect the kidney from fibrosis. We attempted to determine whether the cMet agonistic Ab might reduce fibrosis, the final common pathway for chronic kidney diseases (CKD). A mouse model of kidney fibrosis disease induced by unilateral ureteral obstruction was introduced and subsequently validated with primary cultured human proximal tubular epithelial cells (PTECs). In kidney biopsy specimens from patients with CKD, cMet immunohistochemistry staining showed a remarkable

SUBMITTER: Kim YC 

PROVIDER: S-EPMC6749055 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature